 DALLAS--BUSINESS WIRE--- LTRN--Lantern Pharma Inc. NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. and machine learning M.L. platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present positive preclinical data on the in vivo efficacy of its drug candidate LP-184 for pancreatic cancer at the American Association for Cancer Research AACR Special Conferen 